A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Clinical trial NCT06793215 · RECRUITING
Trial details
- NCT number
- NCT06793215
- Sponsor
- Hoffmann-La Roche
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2025-10-24
- Primary completion
- 2028-11-30
- Enrollment
- 600
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.